Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines
Osimertinib is a third-generation, irreversible EGFR inhibitor that targets common activating EGFR mutations (ex19del and L858R) and the resistance EGFR mutation T790M. Clinical resistance to osimertinib frequently arises through the EGFR C797S mutation, which has driven the development of fourth-generation EGFR in...
Janneke J. Melis, Kirsten J. Kevenaar, J. Ytsma et al.
· Frontiers in Oncology · 0 citations